Palatin Technologies (PTN) Net Equity Issued and Repurchased (2010 - 2026)
Palatin Technologies' (PTN) quarterly Net Equity Issued and Repurchased came in at -$562.0 in Q1 2026, down 100.21% YoY from $271037.0 in Q1 2025, and down 100.02% on a QoQ basis from $3.5 million in Q2 2025.
Palatin Technologies (PTN) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Net Equity Issued and Repurchased data on file, last reported at -$562.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 100.21% year-over-year to -$562.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 1451.06% YoY) and the FY2025 annual result came in at $8.0 million, down 45.72% from the prior year.
- Net Equity Issued and Repurchased eased to -$562.0 in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $10.0 million in Q4 2022 to a low of -$27737.0 in Q2 2024.
- A 5-year average of $3.3 million and a median of $1.0 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased slumped 102.68% — and 2025, when it soared 12730.22%.
- Tracing PTN's Net Equity Issued and Repurchased over 5 years: stood at $10.0 million in 2022, then plunged by 49.81% to $5.0 million in 2023, then slumped by 100.55% to -$27737.0 in 2024, then soared by 12730.22% to $3.5 million in 2025, then tumbled by 100.02% to -$562.0 in 2026.
- The last three Net Equity Issued and Repurchased figures came in at -$562.0 (Q1 2026), $3.5 million (Q2 2025), and $271037.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -562.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -562.00 |
| Mar 31, 2026 | -562.00 |
| Jun 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 271,037.00 |
| Mar 31, 2025 | 271,037.00 |
| Jun 30, 2024 | -27,737.00 |
| Jun 30, 2024 | -27,737.00 |
| Mar 31, 2024 | 9.16 Mn |
| Mar 31, 2024 | 9.16 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Sep 30, 2023 | 531,369.00 |
| Sep 30, 2023 | 531,369.00 |
| Jun 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Dec 31, 2022 | 9.96 Mn |
| Dec 31, 2022 | 9.96 Mn |
| Jun 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 6,000.00 |